Adam P. Dicker, MD, PhD

Adam P. Dicker, MD, PhD, professor, chair, Department of Radiation Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, discusses DNA sequencing for patients with prostate cancer.

According to Dicker, DNA sequencing has become less expensive, making it more accessible for patients. The ability to sequence a patient’s DNA can not only help inform the physician on how a patient will respond to therapy but also how the patient will react to toxicities.

Over the next 5 years with the increase in technology, more information regarding DNA sequencing will become available.

Videos

Dr. Dicker on DNA Sequencing for Prostate Cancer

Adam Dicker, MD, PhD, professor, chair, department of Radiation Oncology Sidney Kimmel Cancer Center, Thomas Jefferson University, discusses the impact of genetic testing for patients with prostate cancer.

Genetic testing has already effected how patients with metastatic prostate cancer are treated, Dicker states.

The standard of care at Thomas Jefferson University, is to do a biopsy of the metastatic site. Then, next-generation sequencing is used and if results determine an alteration in a DNA damaged pathway, the patient may receive a PARP inhibitor or platinum-based therapy, explains Dicker.

Author | Adam P. Dicker, MD, PhD

Articles

Dr. Dicker on DNA Sequencing for Prostate Cancer

Dr. Dicker on the Impact of Genetic Testing for Prostate Cancer